TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician’s Choice of Therapy for Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency (CO-338-063), NCT02975934
PURPOSE OF THIS CLINICAL RESEARCH TRIAL
The purpose of this study is to determine how patients with metastatic castration-resistant prostate cancer, and evidence of a homologous recombination gene deficiency, respond to treatment with rucaparib verses treatment with physician’s choice of abiraterone acetate, enzalutamide, or docetaxel.
MORE DETAILS ON THIS PROSTATE CANCER TRIAL
16238 / NCT02975934 / STAR Trial / PI TBD / Open 9-5-2017
TRIAL AVAILABLE AT THESE LOCATIONS
STAR trial can be opened at any location as patients are identified.